| Size | Price | Stock | Qty |
|---|---|---|---|
| 5g |
|
||
| Other Sizes |
| Targets |
NMDA receptors (NR1/NR2A subtype: IC50 = 3.7 μM; NR1/NR2B subtype: IC50 = 4.2 μM) [1]
|
|---|---|
| ln Vitro |
6-Methoxy-2-naphthoic acid acts as a negative modulator of NMDA receptors, inhibiting glutamate-induced NMDA receptor activation in a concentration-dependent manner. In HEK293 cells heterologously expressing human NR1/NR2A receptors, it inhibited glutamate (10 μM)-evoked inward currents with an IC50 of 3.7 μM; at 10 μM, current amplitude was reduced by 68% [1]
In cells expressing NR1/NR2B receptors, the compound showed similar inhibitory activity, with an IC50 of 4.2 μM and 62% current inhibition at 10 μM. It did not affect AMPA or kainate receptor-mediated currents at concentrations up to 20 μM, indicating subtype-selective inhibition of NMDA receptors [1] In primary cortical neurons, 6-Methoxy-2-naphthoic acid (1-10 μM) dose-dependently reduced NMDA-induced calcium influx. At 10 μM, calcium accumulation was decreased by 59%, without affecting baseline calcium levels or neuronal viability (MTT assay: >92% viability vs. control) [1] |
| Enzyme Assay |
HEK293 cells were transfected with plasmids encoding human NR1 and NR2A/NR2B subunits. After 48 hours of culture, cells were voltage-clamped at -60 mV using the whole-cell patch-clamp technique. 6-Methoxy-2-naphthoic acid (0.1-20 μM) was preincubated with cells for 5 minutes, followed by application of glutamate (10 μM) plus glycine (1 μM) to activate NMDA receptors. Inward currents were recorded, and IC50 values were calculated from concentration-response curves [1]
Calcium influx assay: Primary cortical neurons were loaded with a fluorescent calcium indicator for 30 minutes at 37°C. 6-Methoxy-2-naphthoic acid (1-10 μM) was added, and 10 minutes later, NMDA (50 μM) plus glycine (10 μM) was administered. Fluorescence intensity was measured at excitation/emission wavelengths of 488 nm/525 nm to quantify calcium influx [1] |
| Cell Assay |
HEK293 cell transfection and electrophysiology assay: HEK293 cells were cultured in DMEM supplemented with fetal bovine serum, seeded in 35 mm dishes (2×10⁵ cells/dish), and transfected with NR1/NR2A or NR1/NR2B expression plasmids. After 48 hours, patch-clamp recordings were performed to assess NMDA receptor-mediated currents in the presence of 6-Methoxy-2-naphthoic acid (0.1-20 μM) [1]
Primary cortical neuron culture and calcium imaging: Cortices were isolated from E18 rat embryos, dissociated, and cultured in neurobasal medium. Neurons were seeded in 96-well plates (1×10⁴ cells/well) and cultured for 7 days. After loading with calcium indicator, cells were treated with 6-Methoxy-2-naphthoic acid (1-10 μM) and stimulated with NMDA/glycine. Fluorescence signals were recorded using a microplate reader to measure calcium influx [1] |
| References | |
| Additional Infomation |
6-Methoxy-2-naphthoic acid is a naphthoic acid. 6-Methoxy-2-naphthoic acid is a synthetic small molecule compound classified as a selective negative regulator of the NMDA receptor [1]. Its mechanism of action involves binding to an allosteric site of the NMDA receptor (different from the binding sites of glutamate or glycine), thereby inhibiting glutamate- and glycine-induced receptor activation. This allosteric regulation confers subtype selectivity to NR1/NR2A and NR1/NR2B receptors [1]. Based on its inhibitory activity against the NMDA receptor and low in vitro cytotoxicity, this compound is considered to have potential use in treating diseases associated with NMDA receptor overactivation, such as neurodegenerative diseases, epilepsy, and ischemic brain injury [1].
|
| Molecular Formula |
C12H10O3
|
|---|---|
| Molecular Weight |
202.2060
|
| Exact Mass |
202.063
|
| CAS # |
2471-70-7
|
| PubChem CID |
349181
|
| Appearance |
White to off-white solid powder
|
| Density |
1.263 g/cm3
|
| Boiling Point |
371.1ºC at 760 mmHg
|
| Melting Point |
192-194°C
|
| Flash Point |
147.8ºC
|
| Vapour Pressure |
3.65E-06mmHg at 25°C
|
| LogP |
2.546
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
3
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
15
|
| Complexity |
239
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
YZBILXXOZFORFE-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C12H10O3/c1-15-11-5-4-8-6-10(12(13)14)3-2-9(8)7-11/h2-7H,1H3,(H,13,14)
|
| Chemical Name |
6-methoxynaphthalene-2-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~60 mg/mL (~296.72 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.9454 mL | 24.7268 mL | 49.4535 mL | |
| 5 mM | 0.9891 mL | 4.9454 mL | 9.8907 mL | |
| 10 mM | 0.4945 mL | 2.4727 mL | 4.9454 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
